Perimenopause / menopause

Bremelanotide activates central melanocortin receptors (chiefly MC4R) in hypothalamic circuits governing sexual motivation, acting on the desire pathway rather than on vaginal blood flow or hormones. This matters in menopause because the dominant HRT/estrogen lanes address vasomotor, bone, and genitourinary symptoms but do not directly restore central desire, and low libido frequently persists on adequate HRT.

The pivotal RCT evidence is in premenopausal women only: the two identical Phase 3 RECONNECT trials (1,267 randomized; safety population n=1,247) showed statistically significant but modest gains in desire and reductions in desire-related distress versus placebo (PMID 31599840). A 2024 review of HSDD pharmacotherapy in premenopausal women explicitly cautions about limited efficacy and transparency concerns (PMID 38767282). Postmenopausal use is off-label with no dedicated pivotal trial, so the menopause-specific grade is emerging: the case rests on mechanism and adjacent-population RCT data, not on proof in menopausal women.

Anecdotal community signal only: perimenopausal and postmenopausal women use it off-label as an as-needed subcutaneous injection roughly 45 minutes before anticipated activity, often at reduced 'microdose' amounts (0.5-1.0 mg) to blunt nausea. Reported upsides are episodic increases in desire and arousal; commonly reported downsides are nausea, flushing, and headache, and many discontinue over tolerability. This is user-reported experience, not evidence of efficacy in the postmenopausal population.

Context, not a protocol: the FDA-approved regimen is 1.75 mg subcutaneously as needed, no more than one dose per 24 hours and no more than eight per month. Community postmenopausal use often starts lower (0.5-1.0 mg) for tolerability. Onset is typically within about 45 minutes.

Contraindicated in uncontrolled hypertension and known cardiovascular disease because it causes transient BP rise and heart-rate drop, relevant given rising cardiovascular risk after menopause. It can cause focal hyperpigmentation with repeated dosing and may reduce absorption of concomitant oral drugs (e.g., naltrexone). It treats desire only, not genitourinary syndrome of menopause or dyspareunia, which need local estrogen or other measures.

• Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. ↗
• Pharmacotherapy of Hypoactive Sexual Desire Disorder in Premenopausal Women. ↗

Semaglutide drives weight loss and improves glucose and lipids via appetite suppression and delayed gastric emptying, reducing total and visceral adiposity. This is menopause-relevant because the estrogen decline promotes partitioning of fat into the intra-abdominal (visceral) depot with associated cardiometabolic risk (PMID 22173571), a change HRT only partly offsets, leaving a metabolic gap semaglutide can fill.

Weight-loss and cardiometabolic efficacy rests on strong RCT evidence for the drug class broadly. The menopause-specific synergy claim is weaker: a retrospective cohort of postmenopausal women found greater total body weight loss on semaglutide among hormone-therapy users vs non-users (~16% vs 12% at 12 months), but with only 16 HT users it is hypothesis-generating, not confirmatory (PMID 38446869). Net: strong for metabolic benefit in this population, emerging for the HT-interaction specifically.

Anecdotal community signal only: perimenopausal and postmenopausal women widely use semaglutide (and compounded versions) for menopause-associated weight gain, often at lower 'microdose' titrations than obesity labeling to limit GI effects, and frequently alongside HRT. Reported benefits include central-fat loss and appetite control; reported issues include nausea, muscle-mass loss, and rebound weight after stopping. This reflects user experience, not controlled evidence of a menopause-specific advantage.

Context, not a protocol: approved obesity titration escalates weekly subcutaneous dosing over ~16-20 weeks toward a 2.4 mg maintenance dose; type 2 diabetes formulations run lower (up to 1.0-2.0 mg). Community menopause use often plateaus at lower doses for tolerability and to preserve lean mass.

Contraindicated with personal/family history of medullary thyroid carcinoma or MEN2, and cautioned in pancreatitis and severe gastroparesis. Delayed gastric emptying can alter absorption of co-administered oral agents, including oral contraceptives/oral estrogen. Attention to lean-mass and bone loss matters in menopause, where fracture risk is already rising; it does not treat vasomotor, bone, or sleep symptoms, which remain HRT's lane.

• Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use. ↗
• Longitudinal associations of the endocrine environment on fat partitioning in postmenopausal women. ↗